ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2023
The everolimus eluting Synergy Megatron
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 4 citations in OpenAlex.
- Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Trial
- Posture-Dependent STEMI Due to Extrinsic Compression of the Right Coronary Artery.JACC. Case reports · 2026Article
- Management of Stent Underexpansion and Aorto-ostial Lesions.Interventional cardiology (London, England) · 2024Review
- The everolimus eluting Synergy MegatronCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2023Article
- The ultrathin-strut everolimus-eluting stent in a real-world population: the Everythin multicenter registry.REC, interventional cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 3 countries.
Funding
Abstract
backgroundThe Synergy Megatron
aimsTo report the short- to medium-term clinical outcomes from the European Synergy Megatron
methodsThis registry was an investigator-initiated study conducted at 14 European centers. The primary outcome was target lesion failure (TLF), defined as the composite of cardiovascular death, target vessel myocardial infarction (MI), and target lesion revascularisation.
resultsFive hundred seventy-five patients underwent PCI with Megatron
conclusionsUse of the Synergy Megatron
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.